SEC Form 4 · accession 0001615774-16-005996

Tonix Pharmaceuticals Holding Corp. · TNXP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jun 21, 2016

Accepted (ET)

Jun 21, 2016 · 12:48 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001430306

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.001 par value	Jun 21, 2016	P	25,000	$2.00	A	31,000	I	By spouse
Common Stock, $0.001 par value	holding	—	—		—	80,815	D
Common Stock, $0.001 par value^F1	holding	—	—		—	29,167	I	By Leder Laboratories, Inc.
Common Stock, $0.001 par value^F1	holding	—	—		—	29,167	I	By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 par value^F1	holding	—	—		—	184,628	I	By Lederman & Co., LLC
Common Stock, $0.001 par value^F1	holding	—	—		—	32,457	I	By L&L Technologies, LLC
Common Stock, $0.001 par value^F1	holding	—	—		—	58,972	I	By Targent Pharmaceuticals, LLC

No Table II lines on this filing.